LINC01819 (KPRT4) as a drug target with unique structure and function

Target Name: LINC01819

NCBI ID: G102723854

LINC01819

Other Name(s): KPRT4 | LINC02590 | long intergenic non-protein coding RNA 1819 | Long intergenic non-protein coding RNA 1819

LINC01819 (KPRT4) as a drug target with unique structure and function

LINC01819 (KPRT4) is a gene that encodes a protein known as K-type ATP-binding cassette (KABC) subfamily 4 member 1 (KPRT4). KABCs are a family of transmembrane proteins that play a crucial role in intracellular signaling. They are involved in a wide range of physiological processes, including intracellular signaling, neurotransmission, and chromatin regulation.

Research has identified LINC01819 (KPRT4) as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its unique structure and function make it an attractive target for drug development due to its potential to modulate a wide range of cellular processes.

One of the key reasons for the potential of LINC01819 (KPRT4) as a drug target is its unique structure. LINC01819 (KPRT4) is a 19 kDa protein that consists of a 152 amino acid long extracellular domain and a 36 amino acid long transmembrane region. It has a unique N-terminal region that consists of a 24 amino acid long ?±-helices and a 10 amino acid long ??-helices. This unique ?±-helices structure is thought to play a key role in LINC01819 (KPRT4)'s unique function and stability.

In addition to its unique structure, LINC01819 (KPRT4) has also been shown to have a wide range of physiological functions. For example, LINC01819 (KPRT4) is involved in intracellular signaling, which is critical for the regulation of cellular processes that are essential for life. It is also involved in neurotransmission, which is critical for the function of the nervous system. Additionally, LINC01819 (KPRT4) is involved in chromatin regulation, which is critical for the expression of genes and the regulation of cellular processes.

The potential of LINC01819 (KPRT4) as a drug target is also enhanced by its expression in various tissues and organisms. For example, studies have shown that LINC01819 (KPRT4) is expressed in a wide range of tissues, including brain, heart, and muscle. This makes it an attractive target for drug development due to its potential to modulate a wide range of cellular processes in different tissues.

In addition to its potential as a drug target, LINC01819 (KPRT4) has also been shown to have a potential as a biomarker for various diseases. For example, studies have shown that LINC01819 (KPRT4) is overexpressed in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. This makes it an attractive target for the development of biomarkers for these diseases.

In conclusion, LINC01819 (KPRT4) is a gene that encodes a protein with unique structure and function that makes it an attractive target for drug development. Its unique structure and function, as well as its potential as a drug target and biomarker, make it an attractive target for further research and development.

Protein Name: Long Intergenic Non-protein Coding RNA 1819

The "LINC01819 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01819 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets